Dr. Ivan Dikic at Goethe University, Frankfurt, Germany has been involved in two groundbreaking studies focusing on molecular details underlying neurodegenerative diseases. The studies were conducted by international research teams and were recently published in the journals Nature Neuroscience – “Haploinsufficiency of TBK1 causes familial…
New Insights Into Molecular Mechanisms Underlying Neurodegenerative Diseases – HSAN II and ALS
A new study recently published in the journal PNAS revealed that a new cellular mechanism involving a key protein called hUPF1 can be exploited as a therapeutic strategy for amyotrophic lateral sclerosis (ALS). The study is entitled “Amelioration of toxicity in neuronal models of…
A new study entitled “Syringe-injectable electronics” recently published in the journal Nature Nanotechnology revealed an innovative method to employ tiny electronic devices in the brain, or other parts of the body, as a potential therapy for a wide range of disorders, including neurodegenerative diseases…
Researchers from the University of Toronto (UT) have recently discovered a potential way to detect a genetic predisposition for Amyotrophic Lateral Sclerosis (ALS), before the debilitating symptoms of the disease begin. The study, entitled, “Jump from Pre-mutation to Pathologic Expansion in C9orf72,” was published in the…
Q Therapeutics, Inc., a clinical-stage company committed to find new therapies that might address central nervous system (CNS) diseases, has recently announced that the United States Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug Application (IND) so that Q-Cells’ Phase 1/2a trials can be initiated in patients with amyotrophic lateral sclerosis (ALS). ALS,…
News
Q Therapeutics Announces FDA Clearance of Its Stem Cell Therapy Q-Cells for Human Trials in ALS
Q Therapeutics, Inc., a company focused on adult stem cell therapies for disorders of the central nervous system, recently announced that its product Q-Cells® has received Investigational New Drug (IND) clearance by the U.S. Food and Drug Administration (FDA) for the start of Phase 1/2a clinical trials in…
Sigma-Aldrich Corporation recently announced it has established an agreement with XCell Science to launch genetically engineered human neural differentiated cells and the corresponding culture media to advance research in the neurological diseases field. Together with the product portfolio of Sigma-Aldrich, these new products offer unique tools relevant for the…
In a recent study published in the journal BMC Neurology researchers found that despite the lack of a curative therapy, Amyotrophic Lateral Sclerosis carergivers (including specialized physicians as well as nursing and familial caregivers) can substantially contribute to the maintenance of quality of life (QoL) at the…
According to a recent study published in the journal JAMA Neurology, type 2 diabetes is associated with a diminished risk of amyotrophic lateral sclerosis (ALS). The study revealed that the risk is directly associated with the age at diagnosis of diabetes and the age at diagnosis of…
In a new study entitled “Dietary Vitamin D3 Restriction Exacerbates Disease Pathophysiology in the Spinal Cord of the G93A Mouse Model of Amyotrophic Lateral Sclerosis,” researchers evaluated the effects of a Vitamin D dietary restriction in the pathogenesis of Amyotrophic lateral sclerosis. The study was performed with…
Recent Posts
- New ALS treatment improves survival, leads to function gains in trial
- ALS Network, ALS United calling for ‘bold’ research proposals for funding
- Study finds common medications that could be repurposed to treat ALS
- New eye imaging approach may help distinguish ALS from Alzheimer’s
- After 15 years as an ALS caregiver, I’m still learning from others